Silexion Therapeutics Corp (SLXN) Stock AnalysisSLXNSilexion Therapeutics Corp

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected. It operates in the Healthcare sector.

Silexion Therapeutics is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $0.36, with a staggering year-to-date change of -98.07%. Additionally, the company has a negative EPS of -5.17, indicating ongoing losses, and a forward P/E ratio of 0, suggesting no expected earnings growth. The main risk is the potential for further dilution from the recent public offering priced at $0.65 per share, which could further depress the stock price.